Benitec Biopharma Inc expected to post a loss of 77 cents a share - Earnings Preview

Benitec Biopharma

07/02/2025 14:18

* Benitec Biopharma Inc  BNTC.OQ   BNTC.O  is expected
to show no
change in quarterly revenue when it reports  results on February
11 (estimated) for the period ending December 31 2024
    * 
    * ​LSEG's mean analyst estimate for Benitec Biopharma Inc is
for a
loss of 77 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 7 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Benitec
Biopharma
Inc is $28.00​, above​ its last closing price of $11.48. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2024  -0.50       -0.55      -0.48     Beat    12.7
 Jun. 30 2024  -0.53       -0.49      -1.32     Missed  -170.4
 Mar. 31 2024  -0.78       -0.78      -1.64     Missed  -110​
 Dec. 31 2023  -0.39       -0.39      -2.64     Missed  -576.9
 ​​Sep.        -0.51       -0.51      -2.76     Missed  -441.2
 30 2023                                                
 Jun. 30 2023              -3.23      -2.83     Beat    12.3​
 Mar. 31 2023  -3.40       -3.40      -2.72     Beat    20
 Dec. 31 2022  -1.87       -1.87      -3.40     Missed  -81.8
 This summary was machine generated February 7 at 14:18 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)